This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Ocugen, Inc.
11/4/2026
Good morning and welcome to Occugen's third quarter 2026 financial results and business update. All participants are currently in listen-only mode. Following the speaker's commentary, there will be a question and answer session. I will now turn the call over to Chris Clark, Occugen's VP of Communications. You may begin.
Thank you, operator, and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Atkinson chairman, CEO, and co-founder, who will provide a business update and an overview of our clinical and operational progress. Rita Johnson-Greene, our chief financial officer, is also on the call to provide a financial update for the quarter ended September 30th, 2026. Dr. Mohamed Genead, our chief medical officer, Dr. Arun Upadhyay, our chief scientific officer, and Abhi Gupta, Executive Vice President of Commercial and Business Development, will be available to answer questions following the presentation. This morning, we issued a press release covering our business and operational highlights for the third quarter of 2026. We encourage listeners to review the press release, which is available on our website at ocugen.com. A replay of this call, along with the slide presentation, will be available on the investor section of the Ocugen website. Before we begin, please note that certain statements made during today's discussion may be forward-looking in nature, including those related to our clinical development pipeline, regulatory timelines, commercialization strategy, international expansion, and financial information, and our anticipated cash runway. These statements reflect management's current expectations and are inherently subject to risks, uncertainties, and assumptions that may cause actual results to materially differ from those expressed or implied. We encourage you to review our filings with the Securities and Exchange Commission, including the risk factors detailed therein, for a more comprehensive understanding of these potential risks. Finally, Ocugen's quarterly report on Form 10-Q covering the third quarter of 2026 will be filed today. I will now turn the call over to Dr. Musunuri.
Thank you, Chris, and good morning, everyone. The third quarter was a quarter of execution for Ocugen. We now have all three of our late-stage modified gene therapy programs in Phase 3. We advanced our business development strategy, and we established a presence in Europe to support pre-commercial activities. With three Phase 3 programs underway, we're executing against a clear strategy to advance our pipeline and build our global presence through strategic partnerships to bring our therapies to patients around the world. Our modified gene therapy platform remains the foundation of everything we do Rather than targeting a single mutation, it is designed to address the underlying biology of complex retinal disease by restoring balance across multiple gene networks. The platform is gene agnostic. It is multifactorial, and it is designed to deliver durable benefit from a single, onetime injection. That approach is what allows us to advance one platform across three major causes of blindness, geographic atrophy, Regnaiz Pigmentosa, and Stargardt disease. We remain on track to file three BLAs by 2028, and our next major milestone is clear. Opti 400 is expected to be the first of our phase three programs to read out, with top line data anticipated in the first quarter of 2027. Let me walk you through the progress made across each program this quarter. I will begin OCU 400 in RP, followed by OCU 410ST in Stargardt disease and OCU 410 in GA before handing the call to Rita for the financial update. In OCU 400 for RP, this was an especially productive quarter for the program with progress on clinical, regulatory, and commercial firms. On the clinical side, we completed enrollment in our Phase III line-by-trial with 140 patients. Topline data from the trial are expected in the first quarter of 2027, followed by a planned BLA submission. Our process performance qualification batches are complete, which supports both our BLA and the commercial line supply of ARQ 400. On the commercial side, in October, we completed an exclusive ARQ 400 license deal for the Middle East and North Africa with the routes pharmaceutical. Finalizing the binding term sheet we announced in July. Under the agreement, AcuGEN is eligible for up to $4 million in combined upfront and potential initial development milestone payments, up to $255 million in potential sales milestones and a 22% royalty on net sales. And we will manufacture commercial supply. This is our second reason of Acu400 license following our agreement with Kwongbrong Pharmaceutical in South Korea. On the regulatory and access side, AHQ-400 received provisional approval and priority designation in the Bahamas under its Longevity and Regenerative Therapies Act, or LARTA. We have executed an agreement with a local partner, the Global Alliance for Regenerative Medicine, to coordinate and manage patient care, and we are progressing site readiness and preparation for full LATA approvals. We're advancing toward potential patient enrollment as early as year-end. This pathway is a meaningful step toward expanding access for RP patients while potentially generating commercial revenues. Taken together, the access pathway from the Bahamas and the Roots License Agreement reflect a deliberate strategy. We intend to bring OQ400 to patients in the United States to extend It's reach internationally through regional partnerships that add commercial scale without requiring us to build our own infrastructure in every market. As we build that international reach, we remain focused on the clinical development pathway that will underpin our efforts to bring OCU400 to patients in major markets. Our Phase I-II experience also provides important context for the Phase III Lime Light Study. In a post-hoc analysis, of seven Phase I-II subjects meeting Phase III eligibility criteria. Five of seven treated eyes, or 71.4%, are projected to meet the Phase III responder threshold of at least a two-level improvement on the LDNA scale from baseline at Week 52. LDNA measures functional vision with a wider range and finer resolution than the mobility test used in Phase I-II. addressing the ceiling effect seen in the study. Our previously reported three-year follow-up adds a longer-term perspective. Seven out of eight valuable consented treated subjects, or 88%, showed improvement or preservation of LLVA compared with untreated eyes at year three, with no serious adverse events related to Occi 400 reported through three years. Separately, our phase three power analysis shows that even at hypothetical treatment responder rate of just 20%, compared with 1% in untreated controls, the model estimates 93.2% power to detect a difference on the primary endpoint. We believe these data support both the design of Limelight and the potential of OCU400, and we look forward to top line results in the first quarter of 2027. Turning to OCU410ST for Stargardt disease, a pediatric onset retinal disorder for which there are no approved therapies. We continue to advance our total phase two three guardian trial protocol and we anticipate top line data in the second quarter of 2027 with the BLA submission to follow. Finally, Ocuportin GA, an advanced form of dry age-related macular degeneration and our largest commercial opportunity. This quarter marked an important transition for the program into phase three. In September, we announced the first patient dose in Armada 3, our global phase three clinical trial. We plan to complete trial enrollment next year with the target BLA filing in 2028. Armada 3 is a 237-subject study that randomizes patients two to one to a single subretinal injection of Ocu-410 or untreated control. across the United States, Canada, and Europe. The primary endpoint is GA lesion growth over 12 months. This is the first total gene therapy trial in geographic atrophy. Today's approved GA therapies target a single pathway and require ongoing intrauterine injections as often as monthly. RQ410 is designed to address multiple pathways underlying the disease with a single onetime treatment. We believe that combination of mechanism and durability gives Ocu410 a clear competitive advantage. Here is a snapshot of the market opportunity across our three late-stage development programs. With Ocu410 for GA represents our largest commercial opportunity, we believe all three programs have the potential to generate significant revenue while addressing areas of substantial unmet medical need. With that, I will turn the call over to Rita for the financial update. Rita?
You're reading a preview of the OCGN Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing